title: Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
authors.affiliation: Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Ricklinger Str. 5, 30449, Hannover, Germany. mattern.anika@mh-hannover.de.
authors.forename: A
authors.initials: A
authors.lastname: Koop
authors.forename: I
authors.initials: I
authors.lastname: Satzger
authors.forename: M
authors.initials: M
authors.lastname: Alter
authors.forename: A
authors.initials: A
authors.lastname: Kapp
authors.forename: A
authors.initials: A
authors.lastname: Hauschild
authors.forename: R
authors.initials: R
authors.lastname: Gutzmer
mesh_terms: D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics; D013449:Sulfonamides / Q000008:administration & dosage*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf